LB Pharmaceuticals Inc (LBRX)
| Market Cap | 1.54B |
| Revenue (ttm) | n/a |
| Net Income | -85.69M |
| EPS | -3.81 |
| Shares Out | 32.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 230,557 |
| Open | 47.64 |
| Previous Close | 47.89 |
| Day's Range | 46.37 - 49.25 |
| 52-Week Range | 13.36 - 50.16 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 53.38 (+11.84%) |
| Earnings Date | Aug 11, 2026 |
About LBRX
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for LBRX stock is "Strong Buy." The 12-month stock price target is $53.38, which is an increase of 11.84% from the latest price.
News
LB Pharmaceuticals price target raised to $60 from $45 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on LB Pharmaceuticals (LBRX) to $60 from $45 and keeps a Buy rating on the shares post the Q2 report.
LB Pharmaceuticals price target raised to $69 from $45 at Clear Street
Clear Street analyst Kaveri Pohlman raised the firm’s price target on LB Pharmaceuticals (LBRX) to $69 from $45 and keeps a Buy rating on the shares. The firm sees a…
LB Pharmaceuticals price target raised to $54 from $46 at BMO Capital
BMO Capital raised the firm’s price target on LB Pharmaceuticals (LBRX) to $54 from $46 and keeps an Outperform rating on the shares. The company’s earnings report highlights meaningful strides…
LB Pharmaceuticals price target raised to $53 from $40 at Stifel
Stifel raised the firm’s price target on LB Pharmaceuticals (LBRX) to $53 from $40 and keeps a Buy rating on the shares. After having sat down with CEO Heather Turner…
LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into ne...
LB Pharmaceuticals Slides: Corporate presentation
LB Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
LB Pharmaceuticals Earnings release: Q2 2026
LB Pharmaceuticals released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
LB Pharmaceuticals Quarterly report: Q2 2026
LB Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 11, 2026.
LB Pharmaceuticals management to meet with Piper Sandler
Meeting to be held in New York on August 17 hosted by Piper Sandler.
LB Pharmaceuticals announces $150M private placement
LB Pharmaceuticals (LBRX) announced that it has entered into a securities purchase agreement to sell 3,577,560 shares of its common stock and pre-funded warrants to purchase up to 715,513 shares…
LB Pharmaceuticals Announces $150 Million Private Placement
NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-imp...
LB Pharmaceuticals expects to report results from NOVA-2 clinical trial in 2027
LB Pharmaceuticals (LBRX) announced that based on enrollment projections, it now expects to report topline results from the pivotal Phase 3 NOVA-2 clinical trial of LB-102 in patients with schizophren...
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-imp...
LB Pharmaceuticals initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of LB Pharmaceuticals (LBRX) with an Outperform rating and $46 price target While antipsychotic therapies have been well established in schizophrenia treatment, LB-102 h...
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), today announced that it has granted to Christopher Zergebel, the new Senior V...
LB Pharmaceuticals initiated with an Outperform at Wolfe Research
Wolfe Research analyst Rudy Li initiated coverage of LB Pharmaceuticals (LBRX) with an Outperform rating and $45 price target Lead asset LB-102 should report positive Phase 3 NOVA-2 data in…
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizop...
Clear Street says Neumora failed trial does not impact LB Pharmaceuticals LB-102
Clear Street analyst Kaveri Pohlman keeps a Buy rating and a $45 price target on LB Pharmaceuticals (LBRX). The firm contends that Neumora Therapeutics (NMRA) Phase 3 KOASTAL failure has…
LB Pharmaceuticals Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference
LB-102, a novel antipsychotic with improved potency and tolerability, is advancing through late-stage trials for schizophrenia, bipolar depression, and MDD. The drug shows promise for cognitive and negative symptoms, with a robust IP position and plans for a long-acting injectable.
LB Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
LB-102, a next-generation benzamide antipsychotic, is advancing through late-stage trials for schizophrenia, bipolar depression, and MDD, with strong efficacy, safety, and cognitive benefits. Multiple pivotal readouts are expected through 2029, supporting broad neuropsychiatric expansion.
LB Pharmaceuticals Transcript: AGM 2026
The meeting covered board introductions, two shareholder proposals, and voting. All director nominees were elected and the auditor appointment ratified. No questions were submitted, and voting results will be reported on Form 8-K.
LB Pharmaceuticals to Participate in Upcoming June Investor Events
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizoph...
LB Pharmaceuticals initiated with a Buy at Clear Street
Clear Street analyst Kaveri Pohlman initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $45 price target The firm is citing its “high conviction” in LB-102, an oral…
LB Pharmaceuticals price target raised to $37 from $31 at Roth Capital
Roth Capital raised the firm’s price target on LB Pharmaceuticals (LBRX) to $37 from $31 and keeps a Buy rating on the shares post the Q1 report. The firm has…
LB Pharmaceuticals reports Q1 EPS (67c), consensus (67c)
“With multiple clinical trials ongoing, our focus is on execution to support several clinical readouts over the next three years that have the potential to unlock tremendous value of LB-102…